Key facts
- This page summarizes Gregory Oakes's Form 4 filing for Landos Biopharma, Inc..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 23 May 2024, 17:45.
Gregory Oakes - 23 May 2024 Form 4 Insider Report for Landos Biopharma, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 23 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 May 2024, 17:45:09 UTC
- Prior SEC filing
- 04 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric W. Blanchard, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gregory Oakes filed Form 4 for Landos Biopharma, Inc. on 23 May 2024.
Change
- Previous filing in this sequence was filed on 04 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LABP
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- Shares
- -54,454
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 23 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 54,454
- Exercise price
- Footnotes
- F1, F2
LABP
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -47,529
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 23 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,529
- Exercise price
- $3.70
- Footnotes
- F3
LABP
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -167,724
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 23 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 167,724
- Exercise price
- $7.90
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Gregory Oakes is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents the right to receive one share of Landos Biopharma, Inc., common stock.
Footnote F2
Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger("Effective Time"), each RSU held by the Reporting Person was canceled and converted into the right to receive (a) acash amount equal to $20.42 multiplied by the aggregate number of unvested and outstanding RSUs as of immediately prior to the Effective Time, plus (b) one contractual contingent value right ("CVR") representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each unvested and outstanding RSU, without interest and subject to any applicable withholding taxes.
Footnote F3
Pursuant to the terms of the Merger Agmt, by and among the Issuer, Guarantor, Parent and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, at the Effective Time, this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one CVR representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.